Title |
Methylation-capture and Next-Generation Sequencing of free circulating DNA from human plasma
|
---|---|
Published in |
BMC Genomics, June 2014
|
DOI | 10.1186/1471-2164-15-476 |
Pubmed ID | |
Authors |
Kristina Warton, Vita Lin, Tina Navin, Nicola J Armstrong, Warren Kaplan, Kevin Ying, Brian Gloss, Helena Mangs, Shalima S Nair, Neville F Hacker, Robert L Sutherland, Susan J Clark, Goli Samimi |
Abstract |
Free circulating DNA (fcDNA) has many potential clinical applications, due to the non-invasive way in which it is collected. However, because of the low concentration of fcDNA in blood, genome-wide analysis carries many technical challenges that must be overcome before fcDNA studies can reach their full potential. There are currently no definitive standards for fcDNA collection, processing and whole-genome sequencing. We report novel detailed methodology for the capture of high-quality methylated fcDNA, library preparation and downstream genome-wide Next-Generation Sequencing. We also describe the effects of sample storage, processing and scaling on fcDNA recovery and quality. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 4 | 44% |
India | 2 | 22% |
Unknown | 3 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Scientists | 5 | 56% |
Members of the public | 4 | 44% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 3 | 3% |
Netherlands | 1 | <1% |
Germany | 1 | <1% |
China | 1 | <1% |
Chile | 1 | <1% |
Unknown | 109 | 94% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 37 | 32% |
Student > Ph. D. Student | 25 | 22% |
Other | 14 | 12% |
Student > Master | 8 | 7% |
Lecturer | 4 | 3% |
Other | 13 | 11% |
Unknown | 15 | 13% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 33 | 28% |
Agricultural and Biological Sciences | 32 | 28% |
Medicine and Dentistry | 19 | 16% |
Engineering | 4 | 3% |
Computer Science | 2 | 2% |
Other | 5 | 4% |
Unknown | 21 | 18% |